Entities or tickers associated with Voyager-focused terminology typically pertain to Voyager Therapeutics, a clinical-stage biopharmaceutical enterprise dedicated to discovering and developing transformative gene therapies for severe central nervous system disorders. The company utilizes advanced adeno-associated virus capsid engineering technologies and proprietary discovery platforms to overcome the blood-brain barrier, aiming to deliver targeted genetic medicines that address difficult neurological conditions such as rare genetic diseases and neurodegenerative disorders.